Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats

Carcinogenesis

Volumn 17, Issue 5, 1996, Pages 1051-1056

  Sargent, L M ^a   Dragan, Y P ^b   Sattler, C ^b   Bahnub, N ^b   Sattler, G ^b   Martin, P ^c   Cisneros, A ^d   Mann, J ^c   Thorgeirsson, S ^a   Jordan, V C ^d   Pitot, H C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF READING   (United Kingdom)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ANTIESTROGEN; DEMECOLCINE; IDOXIFENE; TAMOXIFEN CITRATE; TOREMIFENE;

ANEUPLOIDY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; KARYOTYPING; LIVER CELL CULTURE; METAPHASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RAT;

ANEUPLOIDY; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DNA ADDUCTS; ESTROGEN ANTAGONISTS; FEMALE; LIVER; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TOREMIFENE;

EID: 15844385780     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.5.1051     Document Type: Article

References (52)

1. Lerner,L.J. and Jordan,V.C. (1990) Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res., 50, 4177-4189.
2. Jordan,V.C. (1993) Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol., 110, 507-517.
3. Furr,B. and Jordan,V. (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25, 127-205.
4. Powles,T. et al. (1994) The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res. Treat., 31, 73-82.
5. Fischer,B., Constantino,J., Redmond,C. and other members of NSABP (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumors. New Engl. J. Med., 320, 479-484.
6. Vanchieri.C. (1992) Breast cancer study initiated in Italy. J. Natl Cancer Inst., 84, 1555-1556.
7. Greaves,P., Goonetilleke,R., Nunn,G., Topham,J. and Orton,T. (1993) Two year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
8. Hard,G., Iatropolis,M., Jordan,K., Radi,L., Kaltenberg.O., Imondi,A. and Williams,G. (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53, 4534-4541.
9. Hirsamaki,P., Hirsamaki,Y., Nieminen,L. and Payne,B. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a one year study with two antiestrogens. Arch. Toxicol., 67, 49-54.
10. Kangas,L., Nieminen,A. and Blanco,G. (1986) A new triphenylethylene compound. Fc-1157a. I. Hormonal effects. Cancer Chemother. Pharmacol., 17, 103-108.
11. Kallio,S., Kangas,L. and Blanco,G. (1986) A new triphenylethylene compound. Fc-1157a. II. Antitumor effects. Cancer Chemother. Pharmacol., 17, 109-117.
12. VcCague,R., Leclercq,G., Legros,N., Goodman,J., Blackburn.G., Jarman,M. and Foster,A. (1989) Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. J. Med. Chem., 32, 2527-2533.
13. Robinson,S., Parker,C, and Jordan,V.C. (1990) Preclinical studies with toremifene as an antitumor agent. Breast Cancer Res. Treat., 16 (Suppl.). 9-17.
14. Chander,S., McCague,R., Luqumani,Y., Newton,C., Doesett,M., Jarman,M. and Coombes,R. (1991) Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen. new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res., 51, 5851-5858.
15. Szamel,l., Hindy,I., Vincze,B., Eckhardt,S., Kangas,L. and Hajba,A. (1994) Influence of toremifene on the endocrine regulation in breast cancer patients. Eur. J. Cancer, 30A, 154-158.
16. Coombes,R., Haynes,B., Dowsett,M., Quigley,M., English,J., Judson,I., Griggs,L., Potter,G., McCague,R. and Jarman,M. (1995) Idoxifene: report of a phase 1 study in patients with metastatic breast cancer. Cancer Res., 55. 1070-1074.
17. Styles,J., Davies,A., Lim,C., de Matteis,F., Stanley,L., White,I., Yuan,Z. X. and Smith,L. (1994) Genotoxicity of tamoxifen, toremifene epoxide. and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 15, 5-9.
18. Davies,A., Martin,E., White,I., de Matteis,F., Edwards,R., Dorman,B., Heydon,R. and Smith,L. (1995) Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis. 16, 539-545.
19. White,I., de Matteis,F., Davies,A., Smith,L., Crofton-Sleigh,C., Venitt,S., Hewer,A. and Phillips,D. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
20. Sargent,L., Dragan,Y., Bahnub,N., Wiley,J., Sattler,C., Schroeder,P., Sattler,G., Jordan,V.C. and Pitot,H.C. (1994) Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female SD rats. Cancer Res., 54. 3357-3360.
21. Styles,J., Davies,R. and Smith,L. (1995) Comparison of the clastogenic effects induced in rats by tamoxifen and some of its analogues. The Toxicologist, 15, 82(A432).
22. Digernes,V. (1983) Chemical liver carcinogenesis: monitoring of the process by flow cytometric DNA measurements. Environ. Health Perspect., 50, 195-200.
23. Xu,Y.H., Sattler,G. and Pitot,H. (1988) A method for the comparative study of replicative DNA synthesis in GGT-positive and GGT-negative hepatocytes in primary culture isolated from carcinogen-treated rats. In Vitro Cell Dev. Biol., 24. 995-1000.
24. Sattler,C., Sawada,N., Sattler,G. and Pitot,H. (1988) Electron microscopic and time lapse studies of mitosis in cultured rat hepatocytes. Hepatology, 8, 1540-1549.
25. Fried,K. and Wainer,I. (1994) Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high performance liquid chromatography. J. Chromatog. B, 655, 261-268.
26. Robinson,S., Langan-Fahey,S., Johnson,D. and Jordan,V.C. (1991) Metabolites, pharmacodynamics. and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug. Metab. Dispos., 19. 36-43.
27. Jordan,V.C. (1995) Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu. Rev. Pharmacol. Toxicol., 35. 195-211.
28. Kangas,L. (1990) Review of the pharmacological properties of toremifene. J. Steroid Biochem., 36, 191-195.
29. Lien,E., Solheim,E. and Ueland,P. (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res., 51, 4837-4844.
30. Dragan,Y., Fahey,S., Street,K., Vaughan,J., Jordan,V.C. and Pitot,H.C. (1994) Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res. Treat., 31, 11-25.
31. McCague,R., Parr,I. and Haynes,B. (1990) Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes: demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites. Biochem. Pharmacol., 40, 2277-2283.
32. Oestrogens, progestins and combinations (1987) IARC Monographs Suppl. 7 on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer, Lyon, pp. 272-288.
33. Musgrove,E., Wakeling,A. and Sutherland,R. (1989) Points of estrogen antagonists and a calmodulin antagonist within MCF-7 cell cycle. Cancer Res., 49, 2398-2404.
34. Osborne,C., Boldt,D., Clark,G. and Trent,J. (1983) Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res., 43, 3583-3585.
35. Tominaga,T., Yoshida,Y., Matsumoto,A., Hayashi,K. and Kosaki,G. (1993) Effects of tamoxifen and the derivative (TAT) on cell cycle of MCF-7 in vitro. Anticancer Res., 13, 661-665.
36. +2-calmodulin in the activation of hormone binding sites. J. Steroid Biochem., 20. 31-35.
37. +2-calmodulin. Mol. Endocrinol., 2, 167-174.
38. Bouhoute,A. and Leclerq,G. (1992) Antagonistic effect of triphenylethylenic antiestrogens on the association of estrogen receptor to calmodulin. Biochem. Biophys. Res. Commun., 184, 1432-1440.
39. Chafouleas,J., Bolton,W., Hidaka,H., Boyd.A. and Means,A. (1982) Calmodulin and the cell cycle: involvement in regulation of cell-cycle progression. Cell. 28. 41-51.
40. Sasaki,Y. and Hikada,H. (1982) Calmodulin and cell proliferation. Biochem. Biophys. Res. Commun., 104, 451-456.
41. Eilam,Y. and Chernichovsky,D. (1988) Low concentrations of trifluoperazine arrest the cell cycle division cycle of Saccharomyces cerevisiae at two specific stages. J. Gen. Microbiol., 134, 1063-1069.
42. Rasmussen,C. and Means,A. (1987) Calmodulin is involved in regulation of cell proliferation. EMBO J., 6. 3961-3968.
43. Rasmussen,C. and Means,A. (1989) Calmodulin is required for cell-cycle progression during G1 and mitosis. EMBO J., 8, 73-82.
44. Boynton,A., Whitfield,J. and MacManus,J. (1980) Calmodulin stimulates DNA synthesis by rat liver cells. Biochem. Biophys. Res. Commun., 95, 745-749.
45. Serratosa,J., Pujol,M., Bachs,O. and Carafoli,E. (1988) Rearrangement of nuclear calmodulin during proliferative liver cell activation. Biochem. Biophys. Res. Commun., 150, 1162-1169.
46. Veigl,M., Sedwick,W., Niedel,J. and Brabch,M. (1986) Induction of myeloid differentiation of HL-60 with naphthalene sulfonamide calmodulin antagonists. Cancer Res., 46, 2300-2305.
47. Edwards,K., Laughton,C. and Neidle,S. (1992) A molecular modeling study of the interactions between the antiestrogen drug tamoxifen and several derivatives, and the calcium-binding protein calmodulin. J. Med. Chem., 35. 2753-2761.
48. Rowlands,M., Parr,I., McCague,R., Jarman,M. and Goddard,P. (1990) Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen: correlations with cytotoxicity. Biochem. Pharmacol., 40, 283-289.
49. Martin,E., Turtebaub,K., Heydon,R., Davies,A., White,I. and Smith,L. (1995) Characterization of tamoxifen induced DNA adducts formed in rat liver. Toxicologist. 15, 152(811A).
50. DiPaolo,J. and Popescu,N. (1976) Cell transformation. Am. J. Pathol., 85, 709-738.
51. Yoo,H. and Vig,K. (1993) Chromosomes lacking kinetochore proteins: their meta-anaphase location susgests potential malsegregation. Mutagenesis. 8, 553-560.
52. Coombes,R., Jarman,M., Dowsett,M., Chander,S., Rowlands,M., DiSalle,E. and Evans,T. (1993) New endocrine agents for the treatment of breast cancer. Rec. Adv. Cancer Res., 127, 267-275.